Jeffrey W. Elder
Expertise in
14
conditions

Dr. Jeffrey W. Elder

Oncology
Prisma Health Cancer Institute – Seneca
131 Lila Doyle Drive, 
Seneca, SC 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
14
conditions
Prisma Health Cancer Institute – Seneca
131 Lila Doyle Drive, 
Seneca, SC 

Overview

Jeffrey Elder is an Oncologist practicing medicine in Seneca, South Carolina.

Dr. Elder is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Vulvar Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hernia Surgery, and Colonoscopy.

Dr. Elder is board certified in American Board Of Obstetrics And Gynecology. He is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 13 clinical trials. Dr. Elder is currently accepting new patients.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in KY

Board Certifications

American Board Of Obstetrics And Gynecology

Fellowships

University of Kentucky Medical Center

Hospital Affiliations

Prisma Health Greer Memorial Hospital
Prisma Health Greenville Memorial Hospital
Prisma Health Patewood Hospital
Prisma Health Oconee Memorial Hospital
Anmed Health

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Prisma Health Cancer Institute – Seneca
131 Lila Doyle Drive, Seneca, SC 29672
Other Locations
Prisma Health Cancer Institute – Faris Rd.
900 West Faris Road, Greenville, SC 29605

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Biological
Study Phase: Phase 2
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
Enrollment Status: Completed
Publish Date: April 05, 2023
Intervention Type: Drug, Biological
Study Drugs: Vigil Tumor Cells, Atezolizumab
Study Phase: Phase 2
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
View 9 Less Clinical Trials

6 Total Publications

Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
Journal: Cancer gene therapy
Published: October 14, 2020
Similar Doctors
Expertise in
46
conditions
Dr. Ross M. Michels
Hematology | Oncology
Expertise in
46
conditions
Dr. Ross M. Michels
Hematology | Oncology
Referral may be required

Greenville Health System

131 Lila Doyle Dr, 
Seneca, SC 
 (0.1 miles away)
864-888-3717
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ross Michels is a Hematologist and an Oncologist practicing medicine in Seneca, South Carolina. Dr. Michels is highly rated in 46 conditions, according to our data. His clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Myeloproliferative Neoplasms (MPN), Retroperitoneal Liposarcoma, and Colorectal Cancer. Dr. Michels is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required
Before you request

Prisma Health Cancer Institute – Faris Rd.

900 West Faris Road, 
Greenville, SC 
 (33.7 miles away)
864-679-3900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Larry Puls is an Oncologist practicing medicine in Greenville, South Carolina. Dr. Puls is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Vulvar Cancer, Malignant Mixed Mullerian Tumor, Ovarian Cancer, Hernia Surgery, and Salpingo-Oophorectomy. Dr. Puls is board certified in American Board Of Obstetrics And Gynecology. Dr. Puls is currently accepting new patients.

Expertise in
23
conditions
Dr. Carla W. Jorgensen
Oncology | Hematology Oncology
Expertise in
23
conditions
Dr. Carla W. Jorgensen
Oncology | Hematology Oncology
Referral may be required
Before you request

Prisma Health Cancer Institute Multidisciplinary Center – Faris Rd.

890 West Faris Road, Suite 320, 
Greenville, SC 
 (33.7 miles away)
864-455-1200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carla Jorgensen is an Oncologist and a Hematologist Oncology provider practicing medicine in Greenville, South Carolina. Dr. Jorgensen is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Lung Cancer, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). Dr. Jorgensen is board certified in American Board Of Internal Medicine. Dr. Jorgensen is currently accepting new patients.

Frequently Asked Questions about Dr. Jeffrey W. Elder

How do I make an appointment with Dr. Jeffrey W. Elder?

You can book an appointment with Dr. Jeffrey W. Elder by calling their office at 864-888-3717. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeffrey W. Elder a top-rated expert for Vulvar Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeffrey W. Elder is classified as an Distinguished expert for Vulvar Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeffrey W. Elder specialize in?

While Dr. Jeffrey W. Elder is a Oncology, they have specific expertise in Vulvar Cancer, Endometrial Cancer, and Ovarian Carcinosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jeffrey W. Elder participate in research or clinical trials?

Yes. Dr. Jeffrey W. Elder has published 6 articles and abstracts on conditions like Vulvar Cancer. You can view a list of Dr. Jeffrey W. Elder's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jeffrey W. Elder accept my insurance?

Dr. Jeffrey W. Elder accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 864-888-3717 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Elder's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 7 Advanced Conditions
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile